These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 15759048)

  • 1. Regulation of therapeutic apoptosis: a potential target in controlling hypertensive organ damage.
    Deblois D; Tea BS; Beaudry D; Hamet P
    Can J Physiol Pharmacol; 2005 Jan; 83(1):29-41. PubMed ID: 15759048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The time window of apoptosis: a new component in the therapeutic strategy for cardiovascular remodeling.
    Hamet P; Moreau P; Dam TV; Orlov SN; Tea BS; de Blois D; Tremblay J
    J Hypertens Suppl; 1996 Dec; 14(5):S65-70. PubMed ID: 9120687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term organ protection by doxazosin and/or quinapril as antihypertensive therapy.
    Gallego-Delgado J; Lazaro A; Gomez-Garre D; Osende JI; Gonzalez-Rubio ML; Herraiz M; Manzarbeitia F; Fortes J; Fernandez-Cruz A; Egido J
    J Nephrol; 2006; 19(5):588-98. PubMed ID: 17136686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Left ventricular hypertrophy and clinical outcomes in hypertensive patients.
    Ruilope LM; Schmieder RE
    Am J Hypertens; 2008 May; 21(5):500-8. PubMed ID: 18437140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of hypertension based on measurement of blood pressure variability: lessons from animal studies.
    Su DF
    Curr Opin Cardiol; 2006 Sep; 21(5):486-91. PubMed ID: 16900013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of cardiovascular structural changes during long-term antihypertensive therapy.
    Agabiti-Rosei E; Muiesan ML
    J Hum Hypertens; 1991 Aug; 5 Suppl 1():41-7. PubMed ID: 1834845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The organ damage in arterial hypertension].
    Agabiti-Rosei E; Muiesan ML
    Ann Ital Med Int; 1995 Oct; 10 Suppl():99S-107S. PubMed ID: 8562278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discordant effects of beta-blockade on central aortic systolic and brachial systolic blood pressure: considerations beyond the cuff.
    Epstein BJ; Anderson S
    Pharmacotherapy; 2007 Sep; 27(9):1322-33. PubMed ID: 17723086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The future of antihypertensive treatment.
    Israili ZH; Hernández-Hernández R; Valasco M
    Am J Ther; 2007; 14(2):121-34. PubMed ID: 17414579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ESH-ESC guidelines for the management of hypertension.
    Erdine S; Ari O; Zanchetti A; Cifkova R; Fagard R; Kjeldsen S; Mancia G; Poulter N; Rahn KH; Rodicio JL; Ruilope LM; Staessen J; van Zwieten P; Waeber B; Williams B
    Herz; 2006 Jun; 31(4):331-8. PubMed ID: 16810473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Target organ protection from a novel angiotensin II receptor (AT1) vaccine ATR12181 in spontaneously hypertensive rats.
    Zhu F; Liao YH; Li LD; Cheng M; Wei F; Wei YM; Wang M
    Cell Mol Immunol; 2006 Apr; 3(2):107-14. PubMed ID: 16696897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Ouabain- and Adducin-dependent mechanisms of hypertension and cardiovascular remodeling as a novel pharmacological approach.
    Ferrari P; Ferrandi M; Valentini G; Manunta P; Bianchi G
    Med Hypotheses; 2007; 68(6):1307-14. PubMed ID: 17097240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiorenal protective effects of year-long antihypertensive therapy with an angiotensin-converting enzyme inhibitor or a calcium channel blocker in spontaneously hypertensive rats.
    Ishimitsu T; Honda T; Ohta S; Akashiba A; Takahashi T; Kameda T; Yoshii M; Minami J; Takahashi M; Ono H; Matsuoka H
    Am J Hypertens; 2006 Dec; 19(12):1233-40. PubMed ID: 17161768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
    Abassi Z; Armaly Z; Nakhoul F; Hoffman A
    Harefuah; 2008 Jun; 147(6):536-42, 573. PubMed ID: 18693632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small artery remodeling in diabetes mellitus.
    Rizzoni D; Rosei EA
    Nutr Metab Cardiovasc Dis; 2009 Oct; 19(8):587-92. PubMed ID: 19481431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of target organ damage caused by hypertension: therapeutic potential.
    Cohuet G; Struijker-Boudier H
    Pharmacol Ther; 2006 Jul; 111(1):81-98. PubMed ID: 16288809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroblast apoptosis precedes cardiomyocyte mass reduction during left ventricular remodeling in hypertensive rats treated with amlodipine.
    Duguay D; Pesant S; Deschepper CF; deBlois D
    J Hypertens; 2007 Jun; 25(6):1291-9. PubMed ID: 17563544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of renin in blood pressure regulation and therapeutic potential of renin inhibition.
    Ferro A; Gilbert R; Krum H
    Int J Clin Pract; 2006 May; 60(5):577-81. PubMed ID: 16700858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.